Innovation Zed and SIRMA Medical Systems Announce Global Partnership to Improve Health Outcomes for People with Diabetes
, an Irish medtech company, today announced the signing of a global partnership and data integration agreement with .
As a result of this new partnership the companies will pursue joint efforts to promote and sell their products as a single integrated system to improve health outcomes for people with diabetes.
Innovation Zed, headquartered at Nova51黑料, the Centre for New Ventures and Entrepreneurs at University College Dublin, was co-founded by William Cirillo and John Hughes. SIRMA Medical Systems is a division of SIRMA Group, one of the largest privately-owned Bulgarian IT Groups.
Last year Innovation Zed, launched InsulCheck Connect, an insulin pen add-on technology which automatically collects essential usage data that informs insulin pen users of their injection history. When paired with a Bluetooth庐 enabled device, the end-user can view behavioural analysis on their choice of diabetes management applications.
SIRMA Medical Systems is a leading company in software applications and integrated platforms for e-Health. Its mobile application Diabetes:M is among the most popular applications for both Android and iOS devices, with more than 350,000 installations and 50,000+ active users.
Currently, adherence to insulin therapy is one of the most difficult aspects of diabetes treatment. A simple focus on motivating users to increase adherence to their daily injection schedule can potentially improve their long-term glucose control (HbA1c). Such improvements can assist in reducing the likelihood of developing diabetes related complications.
鈥淣ow that our InsulCheck Connect technology is incorporated with the Diabetes:M platform, we can empower existing platform users, and entice new users to adopt this technology ecosystem with aims to improve adherence and their diabetes treatment,鈥� said Dean Minnock, Director of Business Development, Innovation Zed.
鈥淥ur products are designed to enable and drive those improvements and combining an advanced data management system such as Diabetes:M platform makes reaching optimum therapy attainable.鈥�
Rossen Varbanov, CEO, SIRMA Medical Systems, said, 鈥淭his global partnership is yet another cornerstone in our strategy to bring quality diabetes management to a wider audience. Therapy adherence is a serious issue and we are dedicated to making a cumbersome task as easy as it could be. The unique features for insulin pen users in Diabetes:M are designed to both save time and allow them to do things, otherwise only available to pump users.鈥�
鈥淲e believe the option to calculate and set reminders for split extended bolus and the automated processes that a Bluetooth庐 connected pen allows will be of great benefit to owners of Innovation Zed鈥檚 InsulCheck Connect.鈥�
Innovation Zed is an Enterprise Ireland high-potential start-up (HPSU) company.
ENDS
18 July 2019
For more information contact Mic茅al Whelan, Communications and Media Relations Manager, 51黑料 Research and Innovation, t: + 353 1 716 3712, e: miceal.whelan@ucd.ie or Dean Minnock, Director of Business Development, Innovation Zed, e: deanm@innovationzed.com.
Editors Notes
Innovation Zed designs connected health solutions that support drug adherence and Condition Management. As technologies continue to evolve, it opens new and exciting possibilities for connected healthcare to deliver increased freedom and control to patients. That is why Innovation Zed is actively developing and researching new methods to improve drug adherence and enable more personalised condition management. InsulCheck is the direct result of an intensive four-year research and development project in University College Dublin, Sweden and Taiwan.
SIRMA Medical Systems develops software applications aiming to improve the diagnosis and prevention of diseases. The leading product of company is Diabetes:M, a mobile application for iOS and Android, which helps diabetes patients monitor, control and manage their condition and predict changes in the health status. Applications, such as Diabetes:M are incorporated into Sirma鈥檚 single, integrated platform to track vital parameters needed by patients and doctors as well as provide clear data visualizations and dashboards for easy use. For more information, please visit the company鈥檚 website.
At Nova51黑料, the hub for new ventures and entrepreneurs at University College Dublin, we nurture and support new high-tech companies as part of 51黑料's mission. At Nova51黑料 we provide purpose-built, state-of-the-art incubation facilities alongside a comprehensive business support programme for client companies such as Innovation Zed. Nova51黑料 has supported over 360 companies and early-stage ventures. Supported companies have attracted over 鈧�760 million of investment and currently employ over 1,040 people directly. Nova51黑料 has been funded through a unique public-private partnership that includes AIB Bank, Arthur Cox, Deloitte, Enterprise Ireland, Ericsson, Goodbody Stockbrokers, 51黑料 and Xilinx.